Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 12, 2011, Pages 632-639

  Rossi, Elisa ^a,b   Villanacci, Vincenzo ^a   Danesino, Cesare ^c   Donato, Francesco ^a   Nascimbeni, Riccardo ^a   Bassotti, Gabrio ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Barrett's esophagus; Colon; EGFR; Liver; Stomach

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CHROMOSOME 7; CHROMOSOME ANALYSIS; COLON METASTASIS; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL CARCINOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STOMACH CANCER; ADENOCARCINOMA; ANALYTICAL EQUIPMENT; ANEUPLOIDY; BIOSYNTHESIS; COLON TUMOR; DISEASE COURSE; ESOPHAGUS TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE; STOMACH TUMOR;

ADENOCARCINOMA; AGED; ANEUPLOIDY; BARRETT ESOPHAGUS; CHROMOSOMES, HUMAN, PAIR 7; COLONIC NEOPLASMS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 84860644230     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082011001200005     Document Type: Article

References (30)

1. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
2. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-46.
3. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
5. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, et al. Differential effects of gefitinib and cetuximab on nonsmall-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005;97:1185-94.
6. Bralet MP, Paule B, Falissard B, Adam R, Guettier C. Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. Histopathology 2007;50:210-6.
7. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003;9:6461-8.
8. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004;8:448-53.
9. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005;7:75-84.
10. Tsiambas E, Karameris A, Lazaris AC, Talieri M, Triantafillidis JK, Cheracakis P, et al. EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays. Hepatogastroenterology 2006;53:452-27.
11. Galizia G, Lieto E, OrdituraM, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31:1458-68.
12. Mitsui F, Dobashi Y, Imoto I, Inazawa J, Kono K, Fujii H, et al. Nonincidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol 2007;20:622-31.
13. MrhalovaM, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor-its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005;52:338-43.
14. Vermeij J, Teugels E, Bourgain C, Xiangming J, in 't Veld P, Ghislain V, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008;8:3.
15. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
16. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998;90:1080-7. Erratum in: J Natl Cancer Inst 2002;94:633.
17. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Supl. 4):S9-15.
18. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al. Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45.
19. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent nonsmall-cell lung cancer. J Clin Oncol 2005; 23:6829-37.
20. Hamilton SR, Aaltonen LA. WHO Pathology and genetics: tumors of digestive system. IARC Press, Lyon 2000.
21. Cohen D, Lane B, Jin T, Magi-Galluzzi C, Finke J, Rini BI, et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer 2007;5:264-70.
22. Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, et al. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 2008;14:1303-9. Erratum in: Clin Cancer Res 2008;14:2247.
23. Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, LieberMM, et al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 1996;149:1193-9.
24. Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53:890-2.
25. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7.
26. Rossi E, Ubiali A, Cadei M, Balzarini P, Valagussa E, Lucini L, et al. HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH). Appl Immunohistochem Mol Morphol 2006;14:127-31.
27. Cestari R, Villanacci V, Rossi E, Della Casa D, Missale G, Conio M, et al. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Lett 2007;251:278-87.
28. Jönsson M, Ekstrand A, Edekling T, Eberhard J, Grabau D, Borg D, et al. Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clin Pathol 2009;9:8.
29. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004;11:689-708.
30. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 2003;9:1579-89.